Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-25-002702
Filing Date
2025-08-08
Accepted
2025-08-08 16:07:06
Documents
46
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2533523.htm   iXBRL 10-Q 995584
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 22266
3 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 13606
4 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 13735
5 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 5149
6 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 4896
  Complete submission text file 0001178913-25-002702.txt   4516160

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE entx-20250630.xsd EX-101.SCH 60771
8 XBRL CALCULATION FILE entx-20250630_cal.xml EX-101.CAL 33474
9 XBRL DEFINITION FILE entx-20250630_def.xml EX-101.DEF 83403
10 XBRL LABEL FILE entx-20250630_lab.xml EX-101.LAB 869299
11 XBRL PRESENTATION FILE entx-20250630_pre.xml EX-101.PRE 190943
49 EXTRACTED XBRL INSTANCE DOCUMENT zk2533523_htm.xml XML 426595
Mailing Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
Business Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002 972-2-532-7151
Entera Bio Ltd. (Filer) CIK: 0001638097 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38556 | Film No.: 251198440
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)